Glioblastoma Drug Development: 180+ Companies Redefining the Treatment Landscape | Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm

The glioblastoma space is witnessing unprecedented advancements, driven by top industry players.

DelveInsight's 'Glioblastoma Pipeline Insight 2025' report provides comprehensive global coverage of pipeline Glioblastoma therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Glioblastoma pipeline domain.

For Glioblastoma emerging drugs, the Glioblastoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Key Takeaways from the Glioblastoma Pipeline Report
• DelveInsight's Glioblastoma Pipeline analysis depicts a robust space with 180+ active players working to develop 200+ pipeline drugs for Glioblastoma treatment.

• The leading Glioblastoma companies include Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies, Bayer, Chimerix, Aivita Biomedical, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Enterome, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, and others are evaluating their lead assets to improve the Glioblastoma treatment landscape.

• Key Glioblastoma pipeline therapies in various stages of development include Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, Ofranergene Obadenovec (VB-111), LAM561 (2-OHOA), MEDI4736 (durvalumab), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), IGV-001, SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, SONALA-001 + Exablate 2.0 Device, VAL-083 (dianhydrogalactitol), Pomalidomide, MDNA55, BMX-001, Lenvatinib ± Pembrolizumab, Paxalisib (GDC-0084), OKN-007, Temferon, EO2401, INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Selinexor (KPT-330), Olutasidenib (FT-2102), VBI-1901, NOX-A12/olaptesed pegol, Asunercept, and others.

• In January 2025, the FDA indicated that paxalisib (formerly GDC-0084) in glioblastoma (GBM) may support standard approval, but not accelerated approval. Secondary OS data from the GBM-AGILE trial were useful for planning a pivotal phase 3 study, with the FDA and developer aligning on the study design.

• In December 2024, Kazia Therapeutics was informed by the FDA that accelerated approval for its brain cancer drug, paxalisib, is unlikely. The FDA stated that the Phase II/III GBM-AGILE study's overall survival data, showing a 3.8-month improvement in glioblastoma patients, does not meet the criteria for accelerated approval.

• In Oct 2024, the FDA granted Fast Track designation to LP-184, a small-molecule alkylating agent developed by Lantern Pharma for the treatment of glioblastoma (GBM). The Fast Track status aims to accelerate the development and review of LP-184, particularly given the limited treatment options for aggressive brain cancers like GBM.

Request a sample and discover the recent breakthroughs happening in the Glioblastoma pipeline landscape @ https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glioblastoma Overview
Glioblastoma Multiforme (GBM) is the most common and aggressive primary brain tumor, primarily affecting adults, with a poor prognosis despite advancements in diagnostic techniques and therapies. GBM arises from somatic evolution, where cancer cells accumulate mutations, diverging from healthy cells. This cancer progresses through complex molecular and genetic changes, altering key signaling pathways. Due to its tendency to extensively spread through the brain tissue, making complete surgical resection difficult, and its high vascularization, GBM is often fatal.

Common Glioblastoma symptoms include headaches, nausea, personality changes, seizures, cognitive dysfunction, and neurological signs such as focal neurological deficits and cranial nerve issues. In rare instances, patients may experience vertigo or psychiatric symptoms. GBM accounts for 52% of primary brain tumors and 20% of all intracranial tumors.

GBM primarily invades the subcortical areas of the cerebrum (65%), spreading across the temporal (31%), parietal (24%), frontal (23%), and occipital (16%) lobes, often in a combination of these regions. It can also occur in the hypothalamus-thalamus (20%), cerebellum (15%), and rarely in the brain stem and spinal cord. Glioblastoma treatment is challenging, with a focus on surgery, radiation, and chemotherapy, but complete remission is rare due to the tumor's aggressive nature.

Find out more about Glioblastoma medication @ https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glioblastoma Treatment Analysis: Drug Profile
Enzastaurin: Denovo BioPharma
DB102 (enzastaurin) is an orally available investigational first-in-class small molecule, serine/threonine kinase inhibitor of the PKC beta, PI3K, and AKT pathways that has been studied in more than 3,000 patients across a range of solid and hematological tumor types. DB102 was originally developed by Eli Lilly and for which Denovo has acquired worldwide rights. DB102 received Orphan Drug Designation in DLBCL and glioblastoma multiforme (GBM) from the FDA and EMA and Fast Track Designation from the FDA. DB102 is the world's first oral small-molecule kinase inhibitor targeting PKC. A retrospective analysis found that it has significant curative effects in high-risk DLBCL patients who are DGM1 positive. The company has initiated a biomarker guided Phase III clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma multiforme (GBM).

Asunercept: Apogenix
CAN008 (asunercept) is a CD95-Fc fusion protein that binds to the CD95 ligand and blocks the interaction between the ligand and the endogenous CD95 receptor. CAN008 has a unique dual mechanism of action, inhibiting both the invasive growth and migration of tumor cells, as well as T-cell apoptosis, which enhances immune recognition of the cancer. Earlier asunercept glioblastoma multiforme (GBM) clinical trial data showed favorable safety and tolerability, prolonged survival and improved quality-of-life. Asunercept has been granted US FDA Orphan Drug Designation and Orphan Medicinal Product Designation by the European Medicines Agency (EMA) for GBM. It has also been accepted into the EMA's PRIME (Priority Medicines) program, which provides support to medicines that could address unmet medical needs. In China, CAN008 has been classified as a Class 1 New Drug by the National Medical Products Administration. CANbridge holds the rights to develop and commercialize CAN008 for any indication in Greater China and is currently conducting a CAN008 Phase II trial in GBM in China.

Key Glioblastoma Therapies and Companies
• Regorafenib : Bayer
• ONC201 : Chimerix
• AV-GBM-1 : Aivita Biomedical
• Enzastaurin (DB-102) : Denovo Biopharma
• DCVax-L : Northwest Therapeutics
• Ofranergene Obadenovec (VB-111) : VBL Therapeutics
• LAM561 (2-OHOA) : Laminar Pharmaceuticals
• MEDI4736 (durvalumab) : MedImmune
• Tasadenoturev (DNX-2401) : DNAtrix
• ITI-1000 (pp65 DC Vaccine) : Immunomic Therapeutics
• IGV-001 : Imvax
• SurVaxM : MimiVax
• Berubicin : CNS Pharmaceuticals
• GLIOVAC (Sitoiganap) : Epitopoietic Research Corporation (ERC)
• Lerapolturev + Pembrolizumab : Istari Oncology
• SONALA-001 + Exablate 2.0 Device : SonALAsense
• VAL-083 (dianhydrogalactitol) : Kintara Therapeutics
• Pomalidomide : Bristol Myers Squibb
• MDNA55 : Medicenna Therapeutics
• BMX-001 : BioMimetix
• Lenvatinib ± Pembrolizumab : Eisai and Merck Sharp & Dohme
• Paxalisib (GDC-0084) : Kazia Therapeutics
• OKN-007 : Oblato
• Temferon : Genenta Science
• EO2401 : Enterome
• INO-5401+ INO-9012+ LIBTAYO (cemiplimab) : Inovio Pharmaceuticals
• Selinexor (KPT-330) : Karyopharm Therapeutics
• Olutasidenib (FT-2102) : Forma Therapeutics
• VBI-1901 : VBI Vaccines
• NOX-A12/olaptesed pegol : TME Pharma
Learn more about the novel and emerging Glioblastoma pipeline therapies @ https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Glioblastoma Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Glioblastoma Pipeline Report
• Coverage: Global
• Key Glioblastoma Companies: Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies, Bayer, Chimerix, Aivita Biomedical, Northwest Therapeutics, VBL Therapeutics, Laminar Pharmaceuticals, MedImmune, DNAtrix, Immunomic Therapeutics, Imvax, MimiVax, Epitopoietic Research Corporation (ERC), Istari Oncology, SonALAsense, Kintara Therapeutics, Bristol Myers Squibb, Medicenna Therapeutics, BioMimetix, Eisai, Merck Sharp & Dohme, Kazia Therapeutics, Oblato, Enterome, Karyopharm Therapeutics, Forma Therapeutics, VBI Vaccines, TME Pharma, and others.
• Key Glioblastoma Pipeline Therapies: Regorafenib, ONC201, AV-GBM-1, Enzastaurin (DB-102), DCVax-L, Ofranergene Obadenovec (VB-111), LAM561 (2-OHOA), MEDI4736 (durvalumab), Tasadenoturev (DNX-2401), ITI-1000 (pp65 DC Vaccine), IGV-001, SurVaxM, Berubicin, GLIOVAC (Sitoiganap), Lerapolturev + Pembrolizumab, SONALA-001 + Exablate 2.0 Device, VAL-083 (dianhydrogalactitol), Pomalidomide, MDNA55, BMX-001, Lenvatinib ± Pembrolizumab, Paxalisib (GDC-0084), OKN-007, Temferon, EO2401, INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Selinexor (KPT-330), Olutasidenib (FT-2102), VBI-1901, NOX-A12/olaptesed pegol, Asunercept, and others.

Dive deep into rich insights for drugs used for Glioblastoma treatment; visit @ https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Glioblastoma Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Glioblastoma Pipeline Therapeutics
6. Glioblastoma Pipeline: Late-Stage Products (Phase III)
7. Glioblastoma Pipeline: Late-Stage Products (Phase III)
8. Glioblastoma Pipeline: Mid-Stage Products (Phase II)
9. Glioblastoma Pipeline: Early Stage Products (Phase I)
10. Therapeutic Assessment
11. Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Key Companies
14. Key Products
15. Unmet Needs
16. Market Drivers and Barriers
17. Future Perspectives and Conclusion
18. Analyst Views
19. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.